The global cancer biomarkers market was valued at US 12.21 billion in 2018 and is expected to witness a high CAGR of ~13.2% over the forecast period (2022–2029). Cancer biomarkers are biological molecules secreted either by tumors or from tissues in response to cancer, which are then later used to measure and evaluate the cancer growth processes in the body. Cancer biomarkers are used on or for the patients when undergoing curative cancer treatment; these can be further used to follow up the disease condition at the early stage or for the possible recurrent disease.
The global cancer biomarkers market growth is driven by the increasing use of cancer biomarkers in drug discovery and development, increasing research on cancer biomarkers, technological advancements, and the increasing global incidence of cancer.
The presence of potential pipeline candidates is driving the Cancer Biomarkers Market growth
Many pharmaceutical companies are actively investing in the research and development of novel biomarkers for the diagnosis and treatment of cancer. Many potential candidates are in their end stages of development and are projected to give a tremendous boost to the Cancer Biomarkers Market after their launch.
According to the U.S. National Library of Medicine, around 1,515 cancer biomarkers are under clinical trials. For instance, Lund University Hospital in collaboration with South Sweden Breast Cancer Group is currently conducting clinical trials to compare the efficacy and tolerability of atorvastatin (in phase 2). This is evaluated against resistance to endocrine treatment (Fulvestrant/Aromatase Inhibitors) in patients with advanced breast cancer (ABC-SE). The study is estimated to be accomplished by April 2022. The introduction of new biomarkers for cancer screening and diagnosis during the forecast period is anticipated to propel the oncology biomarkers market growth.
According to the World Cancer Research Fund (WCRF) International, 2015 data findings, 58% of the lung cancer cases were reported in emerging economies, in 2014. Hungary had the highest rate of lung cancer, followed by Serbia, and North Korea. Moreover, the highest incidence of lung cancer was registered in North America and Europe, in the same year. According to the National Cancer Institute, in 2014, around 66,771 people were suffering from liver, and intrahepatic bile duct cancer in the U.S. Liver and intrahepatic bile duct cancer represented 2.4% of all new cancer cases reported in the U.S. 2014. Moreover, obesity, diabetes, alcoholic liver disease (cirrhosis), chronic hepatitis B, hepatitis C infections, tobacco, and smoking are the most common risk factors for liver cancer.
According to the Centers for Disease Control and Prevention (CDC), February 2018 data findings, each year in the U.S., around 22,000 men and 9,000 women suffer from liver cancer, and about 16,000 men and 8,000 women die from liver cancer. Thus, the substantial increase in the incidence and mortality rate of liver cancer in the country is expected to boost the growth of the cancer biomarkers market, shortly. All such cancer is paving the way for new cancer diagnostic tests with the use of cancer biomarkers, which might help in the early detection of cancer, which can further impact the prevalence rate of cancer in middle and lower economic countries.
The lack of reimbursement policies for biomarker testing will hamper the market growth
Despite the increasing incidence of cancer globally, and a growing number of patients requiring diagnostic tests, the lack of reimbursement policies for biomarker tests in emerging and developed countries, is one of the factors that is limiting the demand for these biomarkers globally. Another major factor restricting the growth of the market is the high cost of diagnosis and treatment for cancer in emerging countries. This is limiting the number of patients undergoing biomarker testing, and the growing preference of patients toward other low-cost detection tests.
COVID-19 Impact Analysis
The COVID-19 pandemic continues to profoundly impact the function of medical oncology practices across the globe. With constantly evolving recommendations, clinicians are pushed to extrapolate data and apply foundational principles of oncology to balance risks and benefits for each individual and their treatment options. Large registries have been established to collect clinical and outcome data on patients with cancer who become infected with the novel SARS-CoV-2 including the American Society of Clinical Oncology Survey on COVID-19 in Oncology Registry, the American Society of Hematology Research Collaborative COVID-19 Registry, and the COVID-19 and Cancer Consortium.
Given the lack of known cancer antigens and the heterogeneous nature of human cancer, this activation marker-based approach is also commonly employed to observe the expansion phase of the tumor-related T-cell response, thereby functioning as a biomarker of response to immunotherapy. This lack of inherent specificity is an increasingly important consideration amidst the SARS-CoV-2 pandemic, particularly in the context of currently utilized biomarkers of the response to immunotherapy.
The HER-2 segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
HER-2 segment held the largest share in 2021 due to the rising prevalence of breast cancer and increasing awareness about disease diagnosis in both developed and developing countries. This along with new biomarker-based tests being introduced by market players for breast cancer diagnosis, based on liquid biopsy is propelling the demand for these tests globally. The human epidermal growth factor receptor (HER)2 oncoprotein has emerged as an important cellular target for the development of a variety of new cancer therapies.
The method used to define the HER2 status is a major factor in determining who will receive these targeted therapies. The HER2 status can be determined by using either tissue tests to look at the primary tumor cells, or an enzyme-linked immunosorbent assay (ELISA) that measures the circulating levels of the extracellular portion of the HER2 protein. Tissue test (immunohistochemistry and fluorescence in situ hybridization) results indicate that approximately 20-30% of patients with primary breast cancer have a HER2-positive tumor. In the case of establishing HER2 status, it takes more than one type of test to identify patients with HER2-positive tumors. It is highly likely that the introduction of additional targeted drugs to growth factor receptors or to angiogenesis targets will take a variety and combinations of tests to tailor the most appropriate therapy to the patient.
The North American region holds the largest market share of the global cancer biomarkers market
North America accounted for the largest share of the global cancer biomarkers market. The North American cancer biomarkers market's growth can be attributed to the increasing R&D on cancer biomarkers and rising technological advancements in the development of cancer biomarkers. Moreover, the high incidence rate of cancer in the region propels market growth. In addition, various cancer biomarker diagnostics are covered under health insurance in the region. Moreover, the rising awareness and affordability of advanced cancer treatments further drive the North American cancer biomarkers market.
The cancer biomarkers market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, Becton, Dickinson and Company, Merck Millipore, Agilent Technologies among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the cancer biomarkers market globally. For instance, In April 2021, F. Hoffmann-La Roche Ltd. (Switzerland), Launched Elecsys Anti-p53 immunoassay to aid the diagnosis of various cancer types.
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.
ErbB2 (HER2): ErbB2 (HER2) is a receptor tyrosine kinase that is overexpressed in some breast tumors. Herceptin, used in the treatment of metastatic Her2-positive cancer, is a monoclonal antibody targeting this kinase.
The global cancer biomarkers market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 180 (approximate) pages.
Get your free sample proposal with a single click!